Literature DB >> 2028484

Prognostic parameters in spontaneous intracerebral hematomas with special reference to anticoagulant treatment.

J A Rådberg1, J E Olsson, C T Rådberg.   

Abstract

We examined a series of 200 consecutive patients with spontaneous intracerebral hematoma clinically and by computed tomography, excluding patients with trauma, aneurysm, or tumor. Hematoma volume varied from 1 to 230 (average 35) ml, and overall mortality was 30% (60 patients). Of the 200 patients, 14% (28) were receiving anticoagulants; among these 28 patients hematoma volume averaged 72 ml and mortality 57% (16 patients). The 140 survivors were followed for 2-24 months. Our findings indicate that anticoagulation therapy after previous cerebral infarction or embolism of cardiogenic origin did not predispose to intracerebral hemorrhage. Prognosis was poor when the initial level of consciousness was low and the hematoma volume exceeded 50 ml in combination with dilatation of the contralateral ventricle. An intracerebral hematoma of greater than 80 ml volume was always fatal, regardless of therapy. With volumes of 40-80 ml, early surgical evacuation of the lobar hematoma may improve outcome.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2028484     DOI: 10.1161/01.str.22.5.571

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  31 in total

1.  The risk of recurrent stroke after intracerebral haemorrhage.

Authors:  H C Hanger; T J Wilkinson; N Fayez-Iskander; R Sainsbury
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-01-12       Impact factor: 10.154

2.  Primary intracerebral haemorrhage in the Jyväskylä region, central Finland, 1985-89: incidence, case fatality rate, and functional outcome.

Authors:  R Fogelholm; M Nuutila; A L Vuorela
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-07       Impact factor: 10.154

3.  Reversal of warfarin associated coagulopathy with 4-factor prothrombin complex concentrate in traumatic brain injury and intracranial hemorrhage.

Authors:  Vijay Yanamadala; Brian P Walcott; Peter E Fecci; Peter Rozman; Jay I Kumar; Brian V Nahed; Brooke Swearingen
Journal:  J Clin Neurosci       Date:  2014-06-18       Impact factor: 1.961

4.  Symptomatic intracerebral hematomas in posterior circulation stroke patients anticoagulated with heparin.

Authors:  Kyusik Kang; Byung-Woo Yoon
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

Review 5.  Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature.

Authors:  Eric M Bershad; Jose I Suarez
Journal:  Neurocrit Care       Date:  2010-06       Impact factor: 3.210

6.  Warfarin use leads to larger intracerebral hematomas.

Authors:  M L Flaherty; H Tao; M Haverbusch; P Sekar; D Kleindorfer; B Kissela; P Khatri; B Stettler; O Adeoye; C J Moomaw; J P Broderick; D Woo
Journal:  Neurology       Date:  2008-09-30       Impact factor: 9.910

Review 7.  [Intracerebral hemorrhage related to anticoagulant therapy].

Authors:  H B Huttner; E Jüttler; A Hug; M Köhrmann; P D Schellinger; T Steiner
Journal:  Nervenarzt       Date:  2006-06       Impact factor: 1.214

8.  Prophylactic anticoagulation to prevent venous thromboembolism in traumatic intracranial hemorrhage: a decision analysis.

Authors:  Damon C Scales; Jay Riva-Cambrin; Dave Wells; Valerie Athaide; John T Granton; Allan S Detsky
Journal:  Crit Care       Date:  2010-04-20       Impact factor: 9.097

Review 9.  Evolving management of symptomatic chronic subdural hematoma: experience of a single institution and review of the literature.

Authors:  David Balser; Shaun D Rodgers; Blair Johnson; Chen Shi; Esteban Tabak; Uzma Samadani
Journal:  Neurol Res       Date:  2013-04       Impact factor: 2.448

10.  Effectiveness of Factor IX complex concentrate in reversing warfarin associated coagulopathy for intracerebral hemorrhage.

Authors:  Farhan Siddiq; Abdul Jalil; Cara McDaniel; David G Brock; Carissa C Pineda; Rodney D Bell; Kiwon Lee
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.